EUVIMEDEUVIMED entdecken
Multizentrische Studie

Predicting Clinical Response to Benralizumab Using CT Imaging

Arnaud Bourdin, Marie Felicia Beclin, Pascal Chanez, Isabelle Vachier, Laurie Pahus, Erika Nogue, Sarah Skinner, David Galeazzi, Myriam Boulhais, Zakaria Lahmar, Mathilde Volpato, Joana Pissarra und 3 weitere

CHEST · 2026-10 · 170 (4) · 1024-1036

DOI: 10.1016/j.chest.2026.04.040 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CHEST, 2026-10. Verfasst von Arnaud Bourdin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; PhyMedExp, Institut National de la Santé et…. Hauptthemen laut MEDLINE: Asthma, Tomography, X-Ray Computed, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Benralizumab reduces eosinophilia and improves outcomes in most, but not all, patients with asthma. We evaluated whether baseline CT imaging-derived metrics assist in clinical response prognosis after 52 weeks. RESEARCH QUESTION: Are CT imaging-derived measures prognostic of benralizumab response, assessed by exacerbation reduction, lung function, and symptom control at 52 weeks? STUDY DESIGN AND METHODS: This 2-center prospective, open-label study included patients eligible for anti-IL-5α receptor therapy who began benralizumab treatment alongside high-dose background therapy for severe eosinophilic asthma (SEA; > 300/mm3). Baseline variables included CT imaging-derived metrics (parametric response mapping [PRM] small airways disease [SAD] voxels; University of California, San Francisco, mucus plugging; and Lund-Mackay sinus score) and other potential biomarkers (blood eosinophil levels and lung function). The primary outcome was ≥ 50% reduction in exacerbation rates. The secondary outcome was a composite clinical score achieving ≥ 2 of response criteria: ≥ 50% exacerbation reduction, FEV1 increase of > 300 mL, and 5-item Asthma Control Questionnaire score improvement of > 0.5. RESULTS: Of 59 enrolled patients, 47 patients (60% female; median age, 54 years) completed the study with high-quality paired inspiratory and expiratory spirometrically gated CT scans. Forty-two of 47 patients achieved ≥ 50% exacerbation reduction, for which no prognostic factor could be identified. Thirty-five of 47 patients achieved the secondary outcome. Receiver operating characteristic curve analyses indicated that PRM SAD voxels (area under the receiver operating characteristic curve [AUC], 0.693; 95% CI, 0.513-0.873) and sinus score (AUC, 0.714; 95% CI, 0.501-0.928) were robust prognostic factors of responder status, both outperforming blood eosinophil count (AUC, 0.630; 95% CI, 0.428-0.832). INTERPRETATION: Our results show that the CT imaging-derived metrics, PRM SAD voxels, and sinus score were associated with benralizumab response as defined by a composite clinical end point and could be valuable biomarkers for response prognosis in patients with SEA. The high rate of exacerbation reduction limited discrimination of the primary end point. These findings support incorporating CT imaging phenotyping into precision management of SEA and warrant validation in larger cohorts. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03976310; URL: www. CLINICALTRIALS: gov.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaTomography, X-Ray ComputedAntibodies, Monoclonal, HumanizedAnti-Asthmatic AgentsPulmonary EosinophiliaHumansFemaleMaleProspective StudiesMiddle AgedPrognosisAdultTreatment OutcomeRespiratory Function TestsROC Curve

Stichwörter der Autor:innen

ROC curveantibodiesarea under curveasthmabenralizumabbiologic therapybiomarkerseosinophiliaeosinophilshumanslungmonoclonalmucusprospective studiestomography

Substanzen

benralizumabAntibodies, Monoclonal, HumanizedAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Centre Hospitalier Universitaire de Montpellier, Montpellier, France; PhyMedExp, Institut National de la Santé et de la Recherche Médicale, CNRS, Montpellier, France. Electronic addre…
  • IDESP, Institut National de la Santé et de la Recherche Médicale, PreMEdical INRIA, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
  • Aix Marseille Université, APHM, CIC 1409, Hôpital NORD, Chemin des Bourrely, Marseille, France; Aix Marseille Université C2VN, Institut National de la Santé et de la Recherche Médicale U1263, INRAE U 1260, Marseille, Fr…
  • Médecine Biologie Méditerranée, Montpellier, France.
  • Aix Marseille Université, APHM, CIC 1409, Hôpital NORD, Chemin des Bourrely, Marseille, France.
  • Clinical Research and Epidemiology Unit, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.

Förderung

  • AstraZeneca

Zitieren

APA

Bourdin, A., Beclin, M. F., Chanez, P., Vachier, I., Pahus, L., Nogue, E., Skinner, S., Galeazzi, D., Boulhais, M., Lahmar, Z., Volpato, M., Pissarra, J., Lafaye de Micheaux, P., Bommart, S., & Molinari, N. (2026). Predicting Clinical Response to Benralizumab Using CT Imaging. CHEST, 170(4), 1024-1036. https://doi.org/10.1016/j.chest.2026.04.040

Vancouver

Bourdin A, Beclin MF, Chanez P, Vachier I, Pahus L, Nogue E, et al. Predicting Clinical Response to Benralizumab Using CT Imaging. CHEST. 2026;170(4):1024-1036. doi:10.1016/j.chest.2026.04.040

BibTeX
@article{Bourdin2026,
  author = {Bourdin, Arnaud and Beclin, Marie Felicia and Chanez, Pascal and Vachier, Isabelle and Pahus, Laurie and Nogue, Erika and Skinner, Sarah and Galeazzi, David and Boulhais, Myriam and Lahmar, Zakaria and Volpato, Mathilde and Pissarra, Joana and Lafaye de Micheaux, Pierre and Bommart, Sebastien and Molinari, Nicolas},
  title = {Predicting Clinical Response to Benralizumab Using CT Imaging},
  journal = {CHEST},
  year = {2026},
  volume = {170},
  number = {4},
  pages = {1024--1036},
  doi = {10.1016/j.chest.2026.04.040}
}
Kostenlos starten →